Interpace Biosciences (OTCMKTS:IDXG) and Retractable Technologies (NYSE:RVP) Head to Head Contrast

Risk & Volatility

Interpace Biosciences has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, Retractable Technologies has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500.

Profitability

This table compares Interpace Biosciences and Retractable Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Interpace Biosciences	63.46%	493.02%	137.46%
Retractable Technologies	-41.11%	-17.15%	-9.33%

Valuation & Earnings

This table compares Interpace Biosciences and Retractable Technologies”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Interpace Biosciences	$38.73 million	0.23	$24.58 million	($0.02)	-102.30
Retractable Technologies	$38.27 million	0.51	-$7.01 million	($0.42)	-1.54

Interpace Biosciences has higher revenue and earnings than Retractable Technologies. Interpace Biosciences is trading at a lower price-to-earnings ratio than Retractable Technologies, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

5.7% of Interpace Biosciences shares are owned by institutional investors. Comparatively, 7.6% of Retractable Technologies shares are owned by institutional investors. 5.5% of Interpace Biosciences shares are owned by insiders. Comparatively, 59.5% of Retractable Technologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Interpace Biosciences beats Retractable Technologies on 6 of the 11 factors compared between the two stocks.

About Interpace Biosciences

Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.

About Retractable Technologies

Retractable Technologies, Inc. designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession in the United States, rest of North and South America, and internationally. The company offers VanishPoint insulin syringes; tuberculin, insulin, and allergy antigen syringes; small diameter tube adapters; blood collection tube holders; allergy trays; IV safety catheters; Patient Safe syringes and Luer Caps; VanishPoint blood collection sets; EasyPoint needles; and VanishPoint autodisable syringes. It distributes its products through general line and specialty distributor; international distributors; and a direct marketing network. Retractable Technologies, Inc. was incorporated in 1994 and is headquartered in Little Elm, Texas.